Tashkent logs 290 meningococcal cases in four months, and a lesson in what to watch

Uzbekistan has never published epidemiology on invasive meningococcal disease, and meningococcal conjugate vaccines are not on its national immunization schedule [s1]. A report released on 1 October in the CDC journal Emerging Infectious Diseases changes the first of those facts: it documents 290 invasive meningococcal disease cases registered in the capital, Tashkent, during 1 January–14 April 2026, in a country of roughly 36 million people [s1].

A children's epidemic

The disease, caused by the bacterium Neisseria meningitidis, can kill a healthy child within hours of the first symptoms. The Tashkent epidemic fell hardest on the very young. Of the 290 case-patients, 171 (59.0%) were male and 119 (41%) female, with a median age of 36 months [s1]. Children aged 2 to under 5 years were the largest group at 41.0%, followed by 5 to under 10 years (17.6%), 1 to under 2 years (14.5%), and infants under 1 year (5.9%) [s1].

Cases turned up across all 12 of Tashkent's administrative districts, with the highest count in Olmazor (37 cases), and a further 15 cases came from other regions of Uzbekistan [s1]. The epidemic curve climbed sharply through late January and February, peaked during 12–18 February, and then fell through April — a shape the authors read as community-wide spread rather than a single point source [s1].

The number that matters

Outcome data were available for 261 (90.0%) patients, with 29 (10.0%) still unresolved at the 14 April cutoff [s1]. Among those with known outcomes, 237 (90.8%) were discharged alive and 24 (9.2%) died, for an overall case-fatality rate of 8.3% (24 of 290) [s1].

That headline rate, though, hides the report's most practical finding. The investigators recorded five clinical signs for each patient. Fever and hemorrhagic rash were each documented in 165 (63.2%) cases, loss of consciousness in 162 (62.1%), and vomiting in 161 (61.7%) [s1]. All four were common — and none predicted who would die.

The one sign that did was the rarest. Classic meningeal signs — nuchal rigidity, Kernig sign, or Brudzinski sign — appeared in just 8 of 261 patients with known outcomes, or 3.1% [s1]. Yet among those few, the case-fatality rate was 50.0%, against 7.9% in everyone else (odds ratio 11.65, 95% CI 2.71–50.13; Fisher exact test p = 0.003) [s1]. In univariable analysis, meningeal signs were the sole clinical sign significantly associated with death [s1].

Why a rare sign cuts the wrong way

The counterintuitive message is that waiting for the textbook sign of meningitis is a way to miss the patients most at risk. Invasive meningococcal disease often presents as meningococcemia — bloodstream infection with fever and a hemorrhagic rash — moving too fast for the neck stiffness that clinicians are trained to look for to ever develop. When meningeal signs do appear in this setting, they can mark disease that has advanced far enough to be very hard to reverse. The practical implication the data support is early, aggressive treatment on the common signs, rather than confirmation by the one that arrives late.

The investigation used 2018 World Health Organization case definitions, with confirmed cases requiring laboratory identification of N. meningitidis from a sterile site such as blood or cerebrospinal fluid [s1]. That methodological care is part of what makes the report notable: it is a structured, prospective look at a disease Uzbekistan had no published record of before.

The wider pattern

Tashkent is not an isolated event. The authors place it against a broad post-pandemic rebound in invasive meningococcal disease after conjugate-vaccine programs had driven it down across high-income countries [s1]. The United States recorded its highest annual case totals since 2014 during 2023–2024; Spain's Aragon region reported a 27-fold case excess in early 2025; and an outbreak struck Canterbury, England, in early 2026 [s1].

What sets Uzbekistan apart is the gap in defenses. With no meningococcal conjugate vaccine in the national schedule and no prior surveillance baseline, the country entered this epidemic effectively blind to it. The report's closing argument follows directly: serogroup surveillance — to establish which strains are circulating — and the introduction of conjugate vaccination will both be needed to prevent invasive meningococcal disease in Uzbekistan [s1]. The 290 cases are, in that sense, a first data point rather than a closed chapter.

Sources

• Clinical Characterization of Invasive Meningococcal Disease Epidemic, Uzbekistan, 2026 — Emerging Infectious Diseases (CDC), 1 October 2026